2014
DOI: 10.1007/s00280-014-2666-7
|View full text |Cite
|
Sign up to set email alerts
|

Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells

Abstract: We conclude that perturbing the Hsp90 pathway could provide a useful therapeutic strategy in tumors driven by Cks1 overexpression.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
11
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
5
1
1

Relationship

1
6

Authors

Journals

citations
Cited by 13 publications
(11 citation statements)
references
References 38 publications
0
11
0
Order By: Relevance
“…Benzoquinone ansamycin 17-allylamino geldanamycin (17-AAG) is a proteasome inhibitor that is able to stabilize p27 Kip1 by depletion of Cks1, the bridge between SKP2 and p27 Kip1 (Khattar et al 2014). Treatment of colon carcinoma cells with 17-AAG resulted in G 1 cell cycle arrest (Khattar et al 2014).…”
Section: Associated Pathologies and Therapeutic Implicationmentioning
confidence: 99%
See 1 more Smart Citation
“…Benzoquinone ansamycin 17-allylamino geldanamycin (17-AAG) is a proteasome inhibitor that is able to stabilize p27 Kip1 by depletion of Cks1, the bridge between SKP2 and p27 Kip1 (Khattar et al 2014). Treatment of colon carcinoma cells with 17-AAG resulted in G 1 cell cycle arrest (Khattar et al 2014).…”
Section: Associated Pathologies and Therapeutic Implicationmentioning
confidence: 99%
“…Benzoquinone ansamycin 17-allylamino geldanamycin (17-AAG) is a proteasome inhibitor that is able to stabilize p27 Kip1 by depletion of Cks1, the bridge between SKP2 and p27 Kip1 (Khattar et al 2014). Treatment of colon carcinoma cells with 17-AAG resulted in G 1 cell cycle arrest (Khattar et al 2014). Restoring p27 Kip1 levels by influencing its gene expression regulators and rectifying p27 Kip1 mislocalization via targeting SRC, CRM1 and PIM, may also provide new avenue for treatment of a variety of cancers.…”
Section: Associated Pathologies and Therapeutic Implicationmentioning
confidence: 99%
“…28,29 MG-132 is a reversible and cell-permeable inhibitor that primarily acts on the chymotrypsin-like site in the β subunit of the proteasome. Epoximicin is a highly potent, irreversible, and one of the most specific proteasome inhibitors that also primarily reacts with the chymotrypsin-like site.…”
Section: Blocking Of Proteasomal Degradation Pathway Leads To An Inmentioning
confidence: 99%
“…Epoximicin is a highly potent, irreversible, and one of the most specific proteasome inhibitors that also primarily reacts with the chymotrypsin-like site. 28,29 MG-132 is a reversible and cell-permeable inhibitor that primarily acts on the chymotrypsin-like site in the β subunit of the proteasome. 30 293T cells were transfected with HA-tagged BMP2 expression plasmid, pCMV3-HA-BMP2.…”
Section: Blocking Of Proteasomal Degradation Pathway Leads To An Inmentioning
confidence: 99%
“…Hspa5, Hspa8, Hsp90aa1, and Stip1, which are implicated in the progression of colon cancer, were significantly suppressed in several pathways (89)(90)(91)(92)(93)(94). To confirm microarray data, quantitative real-time-PCR (qPCR) was performed on selected induced (i.e., collagen, decorin, mitogen-activated protein KKKK 4, and tissue inhibitor of metalloproteinase 4), suppressed (malate dehydrogenase 1 and angiogenin), or unaltered genes (ATP binding cassette and SMAD family member 6) and a high agreement between microarray and qPCR results was obtained ( Fig.…”
Section: Ctbp Enhances Tgfβ-associated Gene Expression Pathways In Thmentioning
confidence: 99%